盐城地区食管癌化疗患者近期生命质量评价

doi:10.3969/j.issn.1004-616x.2017.06.007

Abstract

Abstract: OBJECTIVE:To assess the quality of life of advanced esophageal cancer patients who received chemotherapy in the Yancheng area,China and to guide the choice of clinical chemotherapy regimens. METHODS:Data on demographic information,disease and treatment,quality of life scale and EORTC QOL-C30 scale were collected from 49 new primary esophageal cancer cases undergoing chemotherapy. Data were collected at one day before chemotherapy and one week,four weeks after chemotherapy. According to five functional areas and three semiotic areas including six single measurement items,and one general health area,scores of QOL were changed into standard measure to analyze demographic data,disease characteristic,patients' QOL before and after chemotherapy and factors influencing patients' QOL undergoing chemotherapy. Software 17.0 was applied to describe and to analyze data including demographic data,disease characteristic,patients' QOL before and after chemotherapy and factors influencing patients' QOL undergoing chemotherapy. RESULTS:Compared with one day before chemotherapy,function score improved one week after chemotherapy. But symptoms of vomit and nausea,pain,insomnia,diarrhea and financial difficulty got worse in general after chemotherapy(P < 0.05). Except social support function,function score increased,and somatic symptoms aggravated more significantly 4 weeks after chemotherapy than that of one day before chemotherapy(P < 0.05). Compared with one week after chemotherapy,physical,role and overall functions improved 4 weeks after chemotherapy(P < 0.05). But symptoms of vomit and nausea,loss of appetite and diarrhea got worse (P < 0.05). Quality of life was related to age,educational level,residence clinical stage,and different routes of metastasis. CONCLUSION:Patients' quality of life after undergoing chemotherapy was affected by duration of chemotherapy,age and educational level,which can be improved by selecting individual scheme and adopting comprehensive management.

Key words: esophageal cancer, chemotherapy, quality of life, evaluation

CLC Number:

R735.1

HE Shuzhi, ZHAO Yue, LIU Yang, YANG Liucai, CHEN Ping, LIU Ran. Evaluation of the quality of life among esophageal cancer patients who received chemotherapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 437-444,449.

References

[1] 庹吉好,魏少忠,李广灿,等. 湖北省不同地区食管/贲门癌(上消化道癌)早诊早治效果分析[J]. 中国肿瘤,2015,24(8):653-656.
[2] 丁颖,苏琼菲,杨帆,等. 食管癌术前同步多西他赛联合顺铂化放疗的临床观察[J]. 中华肿瘤防治杂志,2012,19(9):679-682.
[3] 孙晓凯,刘荣海,周文君. 盐城市居民食管癌死亡趋势及Joinpoint回归分析[J]. 现代预防医学,2010,37(14):2620-2622.
[4] 丁金霞,王婷,王维利,等. 化疗期癌症患者癌因性疲乏与生命质量的研究[J]. 中华疾病控制杂志,2015,19(5):462-465.
[5] AARONSON N K,MEYEROWITZ B E,BARD M,et al. Quality of life research in oncology. past achievements and future priorities[J]. Cancer,1991,67(Sup 3):839-843.
[6] 方积乾. 生存质量测定方法及应用[M]. 北京:北京医科大学出版社,2001:263-267.
[7] SCARPA M,SAAEEH L M,FASOB A,et al. Healthy-related quality of life in patients with oesophageal cancer:analysis at different steps of the treatment path way[J]. J Gastrointest Surg,2013,17(3):421-433.
[8] 王俊,王丽丹,江启成. 我国肿瘤患者生命质量评价研究现状及特点[J]. 中华疾病控制杂志,2017,21(4):422-424.
[9] 钱勇,潘跃银,孙国平,等. 食管癌新辅助化疗患者生活质量的定量研究[J]. 肿瘤研究与临床,2006,18(4):233-236.
[10] 罗利民,贾勇士,吴树强. 卡培他滨联合放疗对老年食管癌患者的治疗效果及生活质量的影响[J]. 中国老年学杂志,2016,36(1):103-105.
[11] 孙佳春,王新帅,刘刚,等. XELOX化疗方案对老年晚期食管癌患者生存质量的影响[J]. 中国老年学杂志,2012,32(22):4915-4916.
[12] 韩振坤,王新帅,王婧婧,等. DCF方案化疗对中晚期食管癌患者生活质量影响的研究[J]. 吉林医学,2011,32(13):2538-2540.
[13] 陈秀芳,李刚,张薛榜,等. 同步放化疗治疗与手术治疗对食管癌患者生活质量影响的比较分析[J]. 温州医学院学报,2013,43(6):371-374.
[14] FAYERS P M,ASRONSON N K,BJORDAL K,et al. On Behalf of the EORTC Quality of Life Study Group. The EORTC QOL-C30 Scoring Manual[M]. 3rd ed. Brussels:EORTC,2001:6-7.
[15] 薛永生,任国琴,涂小妹. 食管癌患者住院生活质量自评量表编制与检验[J]. 中外医学研究,2009,7(13):46-48.
[16] 施朕善,蒋祥德. 生存质量在食管癌中的研究现状[J]. 现代肿瘤医学,2015,23(5):723-726.
[17] 张林,马伟,李云,等. 不同术式对老年食管癌切除术后患者生活质量的影响[J]. 中国老年学杂志,2013,33(20):5017-5018.
[18] LAZEBY J M B,WILLIANS M H,BROOKES S T,et al. Quality of life measurement in patients with oesophageal cancer[J]. Gut,1995,37(4):505-508.
[19] 吴伟英,林白浪,林桦,等. 知信行模式健康教育对食管癌患者健康行为及生存质量的影响[J]. 中国健康教育,2016,32(5):455-461.
[20] 李向青,李荣,任利华,等. 社会支持对食管癌手术后患者生命质量的影响[J]. 现代预防医学,2012,39(13):3314-3315,3317.
[21] 鲁勇国,梅波,万志渝,等. 胸腔镜食管癌切除术后患者近期生命质量的评价[J]. 中国胸心血管外科临床杂志,2016,23(3):248-252.
[22] 李宁. 同期放化疗对食管癌患者近期生存质量的影响[J]. 临床医学,2016,36(8):72-73.
[23] 徐洪波,江浩,张亚军,等. 三维适形放疗联合奥沙利铂加卡培他滨同步化疗治疗Ⅲ期食管癌的疗效[J]. 中国老年学杂志,2015,35(19):5522-5524.
[24] 孙燕. 内科肿瘤学[M]. 北京:人民卫生出版社,2001:534.
[25] 周际昌. 实用肿瘤内科学[M]. 北京:人民卫生出版社,2003:572-588.
[26] 梁青梅,张萍. 食管癌晚期患者临终关怀的护理体会[J]. 基层医学论坛,2010,14(27):827.
[27] 吴天亮. 食管癌量表QLICP-ES的评价及食管癌患者生命质量的分析[D]. 泰安:泰山医学院,2014.
[28] HJERMSTAD M J,FAYERS P M,BJORDAL K,et al. Health related quality of life in the general Norwegian Population assessed by the European organization for research and treatment of cancer core quality of life questionnaire:the QLQ-C30[J]. J Clin Oncol,1998,16(3):1188-1196.
[29] BLAZEBY J M,BROOKES S T,ALDERSON D. Prognostic value of quality of life scores in patients with esophageal cancer[J]. Br J Surg,2000,87(3):362-373.
[30] MIEHELSON H,BLOUND C,NILSSON B,et al. Health-related quality of life measured by the EORTC QLQ-C30 reference values from a large sample of Swedish population[J]. Aetaoneol,2000,39(4):477-484.
[31] BOUCHARDY C,FIORETTAG,D E PERROT M,et al. Determinants of long term survival after survival after surgery for cancer of the lung:A population-based study[J]. Cancer,1999,86(11):2229-2237.
[32] 马红霞,刘艳,罗红格,等. 癌症患者生命质量状况调查及其影响因素分析[J]. 中国健康心理学杂志,2012,20(5):667-668.

Evaluation of the quality of life among esophageal cancer patients who received chemotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	CAI Qi, GAO Deyu, SHI Jianfeng, YU Hao, HAN Yan, YANG Liu, ZHAO Lei, WANG Zhaoxu. Potential use of tree shrew as an animal model for the micronucleus test [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 370-374,382.
[2]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[3]	JIAO Wenjing, GUO Xiujuan, MA Ming, SHAO Junguo, ZHANG Jinyan. Comparative efficacies between concurrent chemo-radiotherapy and radiotherapy alone in elderly patients with locally advanced esophageal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 124-128.
[4]	CHEN Wanxian, WANG Simeng, CHEN Zhangyu, WANG Panji, ZHENG Chunwen, LI Enmin, XU Liyan. CASIN, a CDC42 inhibitor, inhibited viability and migration of esophageal carcinoma cells in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 136-142.
[5]	FENG Min, ABBIE·Mohetar, SHI Jingyi, ZUKELAI·Alijiang, LI Yongxiang, YAN Changshun, LI Xiumei. Expression of miR-143, miR-145 and Survivin mRNA in esophageal cancers among Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 29-32.
[6]	MA Lili, ZHANG Shuli, LI Qin, XU Peng, FENG Min, LI Xiumei. Screening and identification of differentially expressed miRNAs in esophageal cancers among Xinjiang Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 52-56.
[7]	WAN Shuquan, WEI Lijun, WANG Fuhua, ZENG Yong. Expression of miR-200b-3p and PAK2 in chemotherapy-resistant and sensitive ovarian cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 216-221.
[8]	WEI Chao, ZHANG Xiao, GAO Jie. Expression of lncRNA and its prognostic value in pancreatic cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(2): 119-126,132.
[9]	LING Min, YANG Mingjing, LIANG Jie, CHEN Dongya, ZHANG Wei, BIAN Qian. Effects from exposure to nano-TiO₂ on the immune system of offspring of rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(1): 69-72.
[10]	YANG Xingxiao, ZOU Naiyi, LI Qiaofang, ZHANG Xueyuan, SONG Heng, LIU Zhikun, MA Ming, SHAN Baoen, ZHU Shuchai. Significance in expression of RNF2 and PCNA proteins in esophageal squamous cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 254-257.
[11]	GUO Xiao, WANG Rui, WU Juan, JI Xiaokun, WANG Heng, ZHANG Yan, MA Yang, DU Yun. Significance of EGFR gene mutation in fresh cytological specimens of lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(1): 67-70.
[12]	YANG Xingxiao, MA Ming, SHAN Baoen, LI Youmei, SONG Heng, LIU Zhikun, ZHU Shuchai. Effect of cinobufacini on chemotherapy sensitivity and toxicity of human esophageal carcinoma cells in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(2): 96-101.
[13]	WANG Chao, RUAN Hongjie, DOU Jiexiong, DUAN Lian, ZHANG Hongwei. Use of the Vicia faba root tip micronucleus test to monitor the genotoxicity of tap water [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(6): 481-483,490.
[14]	WU Huatao, SHEN Jiaxin, LIU Jing. Overexpression of Notch3 enhance the efficacy of cisplatin to MDA-MB-231 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(2): 111-114,120.
[15]	LI Xiumei, GUO Qiong, WANG Dong, CHEN Yan, LI Hui, CHEN Hongming, LI Huiwu. Expression and significance of miR-143, MMP-2 and TIMP-1 in esophageal cancer in Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(1): 32-35,40.